Literature DB >> 12947377

Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction.

Abhiram Prasad1, Stuart T Higano, Jassim Al Suwaidi, David R Holmes, Verghese Mathew, Geralyn Pumper, Ryan J Lennon, Amir Lerman.   

Abstract

BACKGROUND: Coronary endothelial dysfunction may potentially lead to myocardial ischemia and to the progression of heart failure. Though endothelial dysfunction is associated with advanced heart failure in humans, relatively little is known regarding their temporal relationship. Thus, the current study was designed to test the hypothesis that coronary endothelial dysfunction is present in patients with asymptomatic left ventricular dysfunction. METHODS AND
RESULTS: Three hundred patients without symptoms of heart failure, with normal or mildly diseased coronary arteries at angiography underwent coronary vascular reactivity evaluation using intracoronary adenosine, acetylcholine (ACH) and nitroglycerin. Patients were divided into 2 groups based on the left ventricular ejection fraction (EF): patients with asymptomatic left ventricular dysfunction (ALVD), EF <45% (n = 11); and patients with EF > or =45% (n = 289, controls). Except for a lower high-density lipoprotein level in patients with ALVD, there were no significant differences between the groups in regards to conventional cardiovascular risk factors. There was no difference in the change (mean +/- SE) in epicardial diameter in response to ACH (-21.7% +/- 7.2% vs -13.8% +/- 1.5%, P =.3). The change in coronary blood flow in response to ACH was significantly attenuated in the patients with ALVD when compared to the controls (-18.5% +/- 14.9% vs 74.0% +/- 7.2%, P <.013). By multivariate analysis, EF was an independent predictor of coronary microvascular dilation with ACH (P <.001).
CONCLUSION: The current study demonstrates that coronary microvascular endothelial dysfunction is present in ALVD. Thus, coronary endothelial dysfunction may be an early event in the pathophysiology of heart failure.

Entities:  

Mesh:

Year:  2003        PMID: 12947377     DOI: 10.1016/S0002-8703(03)00364-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

Review 1.  Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment.

Authors:  Yasushi Matsuzawa; Amir Lerman
Journal:  Coron Artery Dis       Date:  2014-12       Impact factor: 1.439

2.  Pseudoexfoliation syndrome and asymptomatic myocardial dysfunction.

Authors:  Lovro Bojić; Ratko Ermacora; Stojan Polić; Milan Ivanisević; Zdravko Mandić; Veljko Rogosić; Mladen Lesin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-14       Impact factor: 3.117

Review 3.  Soluble guanylate cyclase: a potential therapeutic target for heart failure.

Authors:  Mihai Gheorghiade; Catherine N Marti; Hani N Sabbah; Lothar Roessig; Stephen J Greene; Michael Böhm; John C Burnett; Umberto Campia; John G F Cleland; Sean P Collins; Gregg C Fonarow; Phillip D Levy; Marco Metra; Bertram Pitt; Piotr Ponikowski; Naoki Sato; Adriaan A Voors; Johannes-Peter Stasch; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

4.  MnSOD protects against COX1-mediated endothelial dysfunction in chronic heart failure.

Authors:  Jordan D Miller; Veronica A Peotta; Yi Chu; Robert M Weiss; Kathy Zimmerman; Robert M Brooks; Donald D Heistad
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-19       Impact factor: 4.733

Review 5.  Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy.

Authors:  Jenna Dean; Sherwin Dela Cruz; Puja K Mehta; C Noel Bairey Merz
Journal:  Nat Rev Cardiol       Date:  2015-05-26       Impact factor: 32.419

6.  Endothelial function evaluation in idiopathic vs. ischemic dilated cardiomyopathy.

Authors:  Edoardo Pancaldi; Chiara Tedino; Mauro Riccardi; Fabio Alghisi; Giuliana Cimino; Greta Pascariello; Emiliano Calvi; Edoardo Sciatti; Enrico Vizzardi; Marco Metra
Journal:  Am J Cardiovasc Dis       Date:  2022-06-15

Review 7.  The Human Microcirculation: Regulation of Flow and Beyond.

Authors:  David D Gutterman; Dawid S Chabowski; Andrew O Kadlec; Matthew J Durand; Julie K Freed; Karima Ait-Aissa; Andreas M Beyer
Journal:  Circ Res       Date:  2016-01-08       Impact factor: 17.367

Review 8.  Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials.

Authors:  Prabhjot Singh; Shilpa Vijayakumar; Andreas Kalogeroupoulos; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2018-04

Review 9.  Nitric oxide in the pathogenesis of cardiac disease.

Authors:  Leopoldo Raij
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

10.  Natakalim improves post-infarction left ventricular remodeling by restoring the coordinated balance between endothelial function and cardiac hypertrophy.

Authors:  Hong-Min Zhou; Ming-Li Zhong; Yan-Fang Zhang; Wen-Yu Cui; Chao-Liang Long; Hai Wang
Journal:  Int J Mol Med       Date:  2014-09-12       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.